AIM ImmunoTech Inc.: financial analysis
Ratios worked out from 10 fiscal years of AIM ImmunoTech Inc.'s statements, compared with 671 companies in Biotechnology.
AIM ImmunoTech Inc. scorecard#
Passes 1 of the 13 checks that could be worked out: strongest in growth (1 of 3), weakest in valuation (0 of 4). Fiscal year 2025; market cap of Oct 27, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✗Price to sales below its peers' median71.0×Price to sales 71.0× against Biotechnology's median of 8.2×.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 4.92% (2026-11-20).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 3
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-8.62 vs -30.92Diluted EPS -8.62 in fiscal 2025 against -30.92 the year before (report's currency).
- ✓Net income higher than five years earlier-$14 M-$14 M in fiscal 2025 against -$14 M in 2020.
- ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
Profitability0 of 2
- ✗Profitable in the newest year-$14 MNet income -$14 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 3
- ✗Short-term assets cover short-term liabilities0.5×Current ratio 0.53 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-14.4×Operating income -14.4 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year189.1%Diluted shares up 189.1% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Worth a look
- Net loss of $14 million, the 17th loss-making year in a row.
- The share count rose 189.1% in the year.
- Shareholders' equity is negative: -$10 million.
- Operating income covers the interest bill only -14.4 times.
- Liabilities due within a year exceed current assets (current ratio 0.53).
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
3of 8(1 of the nine tests cannot be worked out from the statements on file, so there is no full score)
- Made a profitno
- Operations brought in cashno
- Return on assets roseno
- Cash from operations exceeds profityes
- Long-term debt fell against assetsyes
- Current ratio roseyes
- No new shares issuedno
- Gross margin rosenot on file
- Asset turnover roseno
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Return on equity | — | — | -118.9% | -40.8% | -32.4% | -60.4% | — | |
| Return on assets | -194.0% | -123.8% | -96.7% | -39.6% | -31.3% | -44.3% | 8% |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Debt to equity | — | — | — | — | — | 0.26× | — | |
| Net debt | $2 M | $1 M | — | — | — | $-16 M | 33% | |
| Interest cover | -14.40× | -34.09× | — | — | -269.14× | -22.46× | 57% | |
| Current ratio | 0.53× | 0.44× | 1.68× | 26.71× | 74.94× | 4.40× | 9% | |
| Equity share of assets | -169.2% | -15.3% | 52.8% | 95.0% | 98.6% | 64.1% | 5% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | — | $-15 M | — | $-16 M | $-14 M | $-40 M | — |
How each figure is worked out#
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Debt to equity
- Total debt divided by shareholders' equity. Not given when equity is negative.
- Net debt
- Total debt less cash. Negative means more cash than debt.
- Interest cover
- Operating income divided by the interest paid on debt.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.